Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Price Performance

Shares of EVGN stock opened at $0.65 on Thursday. The firm has a fifty day moving average price of $0.69 and a 200-day moving average price of $0.77. Evogene has a 1 year low of $0.45 and a 1 year high of $1.44. The company has a market cap of $26.81 million, a price-to-earnings ratio of -1.41 and a beta of 1.40.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings data on Thursday, May 23rd. The biotechnology company reported ($0.08) EPS for the quarter. The business had revenue of $4.19 million during the quarter. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%.

Institutional Trading of Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets increased its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 21,500 shares during the period. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 as of its most recent SEC filing. 10.40% of the stock is owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.